Nov 19, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Generate Biomedicines on a series of immunopeptidomics projects. On Nov 18 2021, Generate Biomedicines just announced a Series B financing of $370 million to advance its protein-targeted drug generation platform.
Generate Biomedicines was founded in 2018 by a group of leaders in biomedicine industry including chairman and CEO of Moderna, Noubar Afeyan and Stéphane Bancel, and Nobel Laureate Dr. Frances Arnold.
According to official website, “Generate Biomedicines is a new kind of therapeutics company—existing at the intersection of machine learning, biological engineering, and medicine—pioneering Generative Biology™ to create breakthrough medicines”.
The collaboration between Complete Omics and Generate Biomedicines will utilize our world’s leading ultra-sensitive clinical proteomics and multiomics platforms on a variety of clinical and pharmaceutical projects (details are not disclosed due to agreement).